Asenapine: A Clinical Review of a Second-Generation Antipsychotic

Clinical Therapeutics

Volumn 34, Issue 5, 2012, Pages 1023-1040

  Stoner, Steven C ^a   Pace, Heather A ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Antipsychotic; Asenapine; Bipolar; Dopamine; Mania; Psychosis; Schizophrenia; Serotonin

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; FLUVOXAMINE; GLUCOSE; HALOPERIDOL; ILOPERIDONE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLANZAPINE; PALIPERIDONE; PAROXETINE; PROLACTIN; QUETIAPINE; RISPERIDONE; SEROTONIN 2A RECEPTOR; ZIPRASIDONE;

AGITATION; ANXIETY DISORDER; BIPOLAR DISORDER; BODY WEIGHT; CATATONIC SCHIZOPHRENIA; CHOLESTEROL BLOOD LEVEL; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FOOD DRUG INTERACTION; GLUCOSE BLOOD LEVEL; HEBEPHRENIA; HUMAN; INSOMNIA; LIPID DIET; LIVER DYSFUNCTION; MANIA; MULTICENTER STUDY (TOPIC); NAUSEA; PARANOID SCHIZOPHRENIA; PATIENT COMPLIANCE; PATIENT SATISFACTION; POSITIVE AND NEGATIVE SYNDROME SCALE; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; SCHIZOPHRENIA; SENILE DEMENTIA; SIDE EFFECT; SMOKING; SOMNOLENCE; SYSTEMATIC REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; YOUNG MANIA RATING SCALE;

ANIMALS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CLINICAL TRIALS AS TOPIC; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE; SCHIZOPHRENIA;

EID: 84860741260     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.03.002     Document Type: Review

References (44)

1. Buckley P.F. Treatment of schizophrenia: let's talk dollars and sense [published correction appears in Am J Manag Care. 1998;4:611]. Am J Manag Care 1998, 4:369-383.
2. Csernansky J.G., Mahmoud R., Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002, 346:16-22.
3. Rosenheck R., Perlick D., Bingham S., Liu-Mares W., et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia. JAMA 2003, 290:2693-2702.
4. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004, 161:1-47. American Psychiatric Association, Workgroup on Schizophrenia.
5. Faglioni A., Chengappa R., Soreca I., Chang J. Bipolar disorder and the metabolic syndrome: causal factors, psychiatric outcomes and economic burden. CNS Drugs 2008, 22:655-669.
6. Kessler R.C., Berglund P., Demler O., et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005, 62:593-602.
7. Hirschfeld R.M., Calabrese J.R., Weissman M.M., et al. Screening for bipolar disorder in the community. J Clin Psychiatry 2003, 64:53-59.
8. Merikangas K.R., Akiskal H.S., Angst J., et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the national comorbidity survey replication. Arch Gen Psychiatry 2007, 64:543-552.
9. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002, 159:1-39. American Psychiatric Association, Workgroup on Bipolar Disorder.
10. Lieberman J.A., Stroup T.S., McEvoy J.P., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209-1223.
11. Jones P.B., Barnes T.R.E., Davies L., et al. Randomized controlled trial of the effect on quality of life of second vs. first generation antipsychotic drugs in schizophrenia. Arch Gen Psychiatry 2006, 63:1079-1087.
12. Clozaril (colazapine) [package insert] 2010, Novartis Pharmaceutical Corp, East Hanover, NJ.
13. Risperdal (risperidone) [package insert] 2011, Ortho-McNeil-Janssen Pharmaceuticals, Titusville, NJ.
14. Zyprexa (olanzapine) [package insert] 2010, Eli Lilly and Co, Indianapolis, Ind.
15. Seroquel and Seroquel XR (quetiapine) [package insert] 2011, AstraZeneca Pharmaceuticals, Wilmington, Del.
16. Geodon (ziprasidone) [package insert] 2010, Pfizer Inc, New York, NY.
17. Abilify (aripiprazole) [package insert] 2010, Otsuka Pharmaceuticals, Tokyo, Japan.
18. Risperdal Consta (risperidone) [package insert] 2010, Ortho-McNeil-Janssen Pharmaceuticals, Titusville, NJ.
19. Invega and Invega Sustenna (paliperidone) [package insert] 2010, Ortho-McNeil-Janssen Pharmaceuticals, Titusville, NJ.
20. Saphris (asenapine) [package insert] January 2011, Merck & Co Inc, Whitehouse Station, NJ.
21. Fanapt (Iloperidone) [package insert] 2010, Vanda Pharmaceuticals, Rockville, Md.
22. Saphris (Asenapine) Sublingual Tablets. Briefing Book US Food and Drug Administration, Accessed March 2010. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM173877.pdf.
23. Saphris (Asenapine) Sublingual Tablets. Briefing Document [background package] Schering-Plough Research Institute, Accessed March 2010. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM173876.pdf.
24. Citrome L. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Int J Clin Pract 2009, 63:1762-1784.
25. McIntyre R.S., Cohen M., Zhao J., et al. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disorders 2009, 11:673-686.
26. McIntyre R.S., Cohen M., Zhao J., et al. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord 2010, 122:27-38.
27. McIntyre R.S., Cohen M., Zhao J., et al. Asenapine versus olanzapine in acute mania: a double-bind extended treatment of bipolar mania. Bipolar Disorders 2009, 11:815-826.
28. McIntyre R.S., Cohen M., Zhao J., et al. Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study. J Affect Disord 2010, 126:358-365.
29. Potkin S.G., Cohen M., Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry 2007, 68:1492-1500.
30. Schoemaker J., Naber D., Vrijland P., et al. Long-term assessment of asenapine vs. olanzapine in patients with schizophrenia or schizoaffective disorder. Pharmacopsychiatry 2010, 43:138-146.
31. Kane J.M., Mackle M., Snow-Adami L., et al. A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. J Clin Psychiatry 2011, 72:349-355.
32. Hussar D., Abbas C. New drugs: asenapine, iloperidone, and bepotastine besilate. J Am Pharm Assoc 2010, 50:107-110.
33. Shahid M., Walker G.B., Zorn S.H., et al. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 2009, 2391:65-73.
34. Franberg O., Marcus M.M., Ivanov V., et al. Asenapine elevates cortical dopamine, noradrenaline, and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms. Psychopharmacology 2009, 204:251-264.
35. Ghanbari R., El Mansari M., Shahid M., Blier P. Electrophysiological characterization of the effects of asenapine at 5-HT1A, 5-HT2A, alpha-2 adrenergic and D2 receptors in the rat brain. European Neuropsychopharmacology 2009, 19:177-187.
36. Tarazi F.I., Moran-Gates T., Wong E.H.F., Shahid M. Differential regional and dose-related effects of asenapine on dopamine receptor subtypes. Psychopharmacology 2008, 198:103-111.
37. Franberg O., Wiker C., Marcus M.M., et al. Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. Psychopharmacology 2008, 196:417-429.
38. van de Wetering-Krebbers S.F.M., Jacobs P.L., Kemperman G.J., et al. Metabolism and excretion of asenapine in healthy male subjects. Drug Metab Disposition 2011, 39:580-590.
39. Weber J., McCormack P.L. Asenapine. CNS Drugs 2009, 23:781-792.
40. Shahid M., Walker G.B., Zorn S.H., et al. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 2009, 23:65-73.
41. Tarazi F.I., Kee Choi Y., Gardner M., et al. Asenapine exerts distinctive regional effects on inotropic glutamate receptor subtypes in rat brain. Synapse 2009, 63:413-420.
42. Den Boer J., Korf J. Dopamine receptor subtypes and schizophrenia: a clinical perspective. Atypical Antipsychotics 2000, 163-190. Birkhäuser Verlag, Basel, Switzerland. B.A. Ellenbroek, A.R. Cools (Eds.).
43. Dogterom P., Hulskotte E., Gerrits M., et al. Asenapine pharmacokinetics: influence of cytochrome P450 modulators and UDP-glucuronyltransferase inhibition. Eur Neuropsychopharmacol 2008, 18(Suppl 4):S4452-S4453. Abstract P.3.d008.
44. Peeters P., Bockbrader H., Spaans E., et al. Asenapine pharmacokinetics in hepatic and renal impairment. Clin Pharmacokinet 2011, 50:471-481.